Aug 2026· Reviews in Medical Virology· Vol 36 5, pp.
e70167
· 0 citations· 62 references
Medicine
TL;DR
The present review provides a comprehensive overview of novel viral candidates in oncolytic virotherapy, their molecular mechanisms of tumour targeting, and current advancements in genetic engineering aimed at improving therapeutic efficacy and biosafety.
Abstract
Oncolytic virotherapy has recently emerged as a promising immuno-oncological strategy, utilising the natural cytolytic potentials of viral pathogens to selectively target and destroy malignant cells. Although various engineered viruses, such as adenoviruses, vaccinia virus, and herpes simplex virus, are currently in clinical evaluation, emerging and re-emerging viruses with intrinsic oncolytic potential, including Zika virus (ZIKV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Dengue virus (DENV), and West Nile virus (WNV), have also shown promising results. These emerging and re-emerging viral pathogens show specific tumour tropism, immune evasion strategies, and immunogenic cell death mechanisms that could be harnessed for next-generation therapeutic platforms. Nonetheless, concerns related to safety, viral pathogenicity, host immune responses, and the risk of uncontrolled viral dissemination present significant translational challenges. The present review provides a comprehensive overview of novel viral candidates, including ZIKV, SARS-CoV-2, DENV, and WNV, in oncolytic virotherapy, their molecular mechanisms of tumour targeting, and current advancements in genetic engineering aimed at improving therapeutic efficacy and biosafety. Moreover, this review describes clinical perspectives, regulatory considerations, and future directions in integrating emerging virotherapeutic agents into precision oncology.
Oncolytic virotherapy has emerged as a promising cancer treatment that combines selective tumor destruction with potent stimulation of antitumor immunity. Unlike conventional therapies, oncolytic viruses (OVs) preferentially infect and replicate within malignant cells while sparing normal tissues, leading to direct tum...
Esraa M. Halawa, Sherihan G. Abdelhamid, Mahmoud M. Elhefnawi· Clinical and Experimental Me...· 0 citations
Oncolytic Virotherapy (OVT) is an emerging area of cancer immunotherapy
that has shown promise as a therapeutic agent, leveraging genetically engineered replication-
competent viruses that kill cancer cells without harming normal cells. HSV-1 (T-VEC),
vaccinia, and adenoviruses. Immuno-Oncology Oncol Ther 2017; Mon...
Indu Arora, Shalu Attar, Priyanka Bhardwaj et al.· Clinical Cancer Drugs· 0 citations
This review aims at assessing the latest advancements in the field of nanotechnology in terms of developing therapeutic interventions in viral diseases, especially COVID-19 and other emerging viral infections.
Abhishek Kumar, Anamika Gaurishankar Parihar· Journal of Drug Delivery and...· 0 citations
Virus-specific T-cell (VST) therapy has developed principally for persistent or reactivating viral infections in immunocompromised patients, with the strongest clinical experience involving cytomegalovirus, Epstein–Barr virus, human adenovirus, BK polyomavirus and human herpesvirus 6. Whether this approach can be exten...
Caroline Mangare· Journal of Clinical Care and...· 0 citations
Oncolytic virotherapy (OVT) is a promising anticancer strategy, owing to its capacity to lyse tumor cells selectively and remodel the tumor microenvironment (TME) to enhance antitumor efficacy. Despite the continuous introduction and investigation of newly engineered oncolytic viruses (OVs) in clinical trials, their cl...
This review examines how genetic, transcriptional, metabolic, epigenetic, and immune heterogeneity influence viral entry, replication, dissemination, and therapeutic activity in glioma and compares established and emerging platforms.
A. Romanishin, K. Rubina, E. Semina· Pathology, Research and Prac...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.